Renal protection strategies after heart transplantation

Daniel Reichart; Hermann Reichenspurner; Markus Johannes Barten

doi:10.1111/ctr.13157

Renal protection strategies after heart transplantation

Standard

Renal protection strategies after heart transplantation. / Reichart, Daniel; Reichenspurner, Hermann ; Barten, Markus Johannes.

In: CLIN TRANSPLANT, Vol. 32, No. 1, 01.2018.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Reichart, D, Reichenspurner, H & Barten, MJ 2018, 'Renal protection strategies after heart transplantation', CLIN TRANSPLANT, vol. 32, no. 1. https://doi.org/10.1111/ctr.13157

APA

Reichart, D., Reichenspurner, H., & Barten, M. J. (2018). Renal protection strategies after heart transplantation. CLIN TRANSPLANT, 32(1). https://doi.org/10.1111/ctr.13157

Vancouver

Reichart D, Reichenspurner H , Barten MJ. Renal protection strategies after heart transplantation. CLIN TRANSPLANT. 2018 Jan;32(1). https://doi.org/10.1111/ctr.13157

Bibtex

@article{69ba6c039e0343a28bceea9e2660bf09,

title = "Renal protection strategies after heart transplantation",

abstract = "Renal dysfunction caused by calcineurin inhibitor (CNI) nephrotoxicity occurs often and contributes significantly to late mortality after heart transplantation (HTx). Over the last decades, this has prompted many clinical studies in an effort to develop kidney-protecting immunosuppressive strategies including delayed CNI start, minimization, withdrawal, or even de novo CNI avoidance. In the past, these strategies often failed due to the lack of efficacy. Since 2009, novel CNI-reducing strategies have been under investigation. These strategies minimize renal damage using induction agents such as antithymocyte globulin and alternative immunosuppressive agents such as the mechanistic target of rapamycin inhibitors (sirolimus or everolimus) or mycophenolate. This review outlines the recent results of using these renal protection strategies including their drawbacks. We also discuss alternative approaches to optimize individual immunosuppressive therapies after HTx.",

keywords = "Heart Diseases/surgery, Heart Transplantation/adverse effects, Humans, Immunosuppressive Agents/therapeutic use, Kidney Diseases/etiology, Prognosis",

author = "Daniel Reichart and Hermann Reichenspurner and Barten, {Markus Johannes}",

note = "{\textcopyright} 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.",

year = "2018",

month = jan,

doi = "10.1111/ctr.13157",

language = "English",

volume = "32",

journal = "CLIN TRANSPLANT",

issn = "0902-0063",

publisher = "Wiley-Blackwell",

number = "1",

}

RIS

TY - JOUR

T1 - Renal protection strategies after heart transplantation

AU - Reichart, Daniel

AU - Reichenspurner, Hermann

AU - Barten, Markus Johannes

PY - 2018/1

Y1 - 2018/1

N2 - Renal dysfunction caused by calcineurin inhibitor (CNI) nephrotoxicity occurs often and contributes significantly to late mortality after heart transplantation (HTx). Over the last decades, this has prompted many clinical studies in an effort to develop kidney-protecting immunosuppressive strategies including delayed CNI start, minimization, withdrawal, or even de novo CNI avoidance. In the past, these strategies often failed due to the lack of efficacy. Since 2009, novel CNI-reducing strategies have been under investigation. These strategies minimize renal damage using induction agents such as antithymocyte globulin and alternative immunosuppressive agents such as the mechanistic target of rapamycin inhibitors (sirolimus or everolimus) or mycophenolate. This review outlines the recent results of using these renal protection strategies including their drawbacks. We also discuss alternative approaches to optimize individual immunosuppressive therapies after HTx.

AB - Renal dysfunction caused by calcineurin inhibitor (CNI) nephrotoxicity occurs often and contributes significantly to late mortality after heart transplantation (HTx). Over the last decades, this has prompted many clinical studies in an effort to develop kidney-protecting immunosuppressive strategies including delayed CNI start, minimization, withdrawal, or even de novo CNI avoidance. In the past, these strategies often failed due to the lack of efficacy. Since 2009, novel CNI-reducing strategies have been under investigation. These strategies minimize renal damage using induction agents such as antithymocyte globulin and alternative immunosuppressive agents such as the mechanistic target of rapamycin inhibitors (sirolimus or everolimus) or mycophenolate. This review outlines the recent results of using these renal protection strategies including their drawbacks. We also discuss alternative approaches to optimize individual immunosuppressive therapies after HTx.

KW - Heart Diseases/surgery

KW - Heart Transplantation/adverse effects

KW - Humans

KW - Immunosuppressive Agents/therapeutic use

KW - Kidney Diseases/etiology

KW - Prognosis

U2 - 10.1111/ctr.13157

DO - 10.1111/ctr.13157

M3 - SCORING: Review article

C2 - 29151264

VL - 32

JO - CLIN TRANSPLANT

JF - CLIN TRANSPLANT

SN - 0902-0063

IS - 1

ER -